<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01271374</url>
  </required_header>
  <id_info>
    <org_study_id>AVR-2010-001</org_study_id>
    <nct_id>NCT01271374</nct_id>
  </id_info>
  <brief_title>Changes in Endothelial Function and Biomarkers in African Americans (AA) With Metabolic Syndrome</brief_title>
  <acronym>AMORE</acronym>
  <official_title>Changes in Central Aortic Pressure, Endothelial Function and Biomarkers in African Americans With Cardiometabolic Syndrome: Comparison of Amlodipine/Olmesartan Versus Hydrochlorothiazide/Losartan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InVasc Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InVasc Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to compare the effects of Azor (a combination of amlodipine and
      olmesartan) with Hyzaar ( a combination of losartan and hydrochlorothiazide) on the thin
      lining on the inside of blood vessels. These cells help keep blood vessels healthy and blood
      pressure normal.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants must be 18-75 years of age, African American, and have a combination of high
      blood pressure, insulin resistance (Type 2 Diabetes), low HDL cholesterol levels or obesity.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>April 2010</start_date>
  <completion_date type="Anticipated">December 2011</completion_date>
  <primary_completion_date type="Anticipated">June 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Central Aortic Pressure (CAP)</measure>
    <time_frame>14 weeks</time_frame>
    <description>The primary efficacy endpoints, defined as the change from baseline of Central Aortic Systolic Pressure (CAP) and the change in brachial artery reactivity (BART) via ultrasound testing, will be compared at the end of 14 weeks of randomized treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood pressure control</measure>
    <time_frame>25 weeks</time_frame>
    <description>Secondary endpoints of percentage of subjects achieving BP goals will be analyzed using Cochran-Mentel-Haenzsel test.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Hyzaar-Treatment Arm B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Weeks 1-2: Hyzaar® 50/12.5 Weeks 3-14: Hyzaar® 100/25 Weeks 15-18: Azor® 10/40+HCTZ 25 Weeks 19-20: Azor® 10/40+HCTZ 25 + spironolactone 25 once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Azor-Treatment A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Weeks 1-2: Azor® 5/20 Weeks 3-14: Azor® 10/40 Weeks 15-18: Azor® 10/40+HCTZ 25 Weeks 19-20: Azor® 10/40+HCTZ 25 + spironolactone 25 once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>amlodipine and olmesartan</intervention_name>
    <description>Weeks 1-2: Azor® 5/20 Weeks 3-14: Azor® 10/40 Weeks 15-18: Azor® 10/40+HCTZ 25 Weeks 19-20: Azor® 10/40+HCTZ 25 + spironolactone 25 once daily</description>
    <arm_group_label>Azor-Treatment A</arm_group_label>
    <other_name>Azor</other_name>
    <other_name>Hydrochlorothiazide</other_name>
    <other_name>Spironoloactone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>losartan and HCTZ</intervention_name>
    <description>Weeks 1-2: Hyzaar® 50/12.5 Weeks 3-14: Hyzaar® 100/25 Weeks 15-18: Azor® 10/40+HCTZ 25 Weeks 19-20: Azor® 10/40+HCTZ 25 + spironolactone 25 once daily</description>
    <arm_group_label>Hyzaar-Treatment Arm B</arm_group_label>
    <other_name>Hyzaar</other_name>
    <other_name>Azor</other_name>
    <other_name>Hydrochlorothiazide</other_name>
    <other_name>Spironolactone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  African American

          -  Hypertension and one of the following:

          -  Fasting glucose &gt; 100 mg/dl

          -  HgA1C&gt; 6.0 %

          -  Plasma triglycerides &gt;150

          -  HDL cholesterol &lt; 40 mg/dl in men or &lt; 50 mg/dl in women

        Exclusion Criteria:

          -  History of Heart failure

          -  use of insulin

          -  non-dominant arm circ &gt; 50 cm.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bobby V Khan, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Director, Atlanta Clinical Research Centers</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Keith C Ferdinand, MD</last_name>
    <role>Study Director</role>
    <affiliation>Atlanta Clinical Research Centers</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Atlanta Clinical Research Center</name>
      <address>
        <city>Tucker</city>
        <state>Georgia</state>
        <zip>30084</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2011</study_first_submitted>
  <study_first_submitted_qc>January 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2011</study_first_posted>
  <last_update_submitted>May 4, 2011</last_update_submitted>
  <last_update_submitted_qc>May 4, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 5, 2011</last_update_posted>
  <responsible_party>
    <name_title>Bobby Khan, MD PhD</name_title>
    <organization>Atlanta Clinical Research Center</organization>
  </responsible_party>
  <keyword>African American</keyword>
  <keyword>Hypertension</keyword>
  <keyword>Cardiometabolic Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olmesartan</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Losartan</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
    <mesh_term>Olmesartan Medoxomil</mesh_term>
    <mesh_term>Amlodipine Besylate, Olmesartan Medoxomil Drug Combination</mesh_term>
    <mesh_term>Spironolactone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

